Revenue Growth: 9% increase in constant currency, 4% in reported currency. Normalized EBITDA: Up 21% in constant exchange rate (CER), 12% in reported currency. Gross Margin: Growth above 20%. Normalized Headline Earnings Per Share: Increased by 17% to ZAR7.24. Commercial Pharma Revenue: Double-digit growth in both revenue and EBITDA. Manufacturing Revenue: 0% growth reported, but 20% underlying growth excluding heparin. FDF Growth: 65% increase over the first half of the previous year. Operating Cash Flow Conversion Rate: Forecast to exceed 100%. Effective Tax Rate: Increased to 21.6% for normalized tax rate. Interest Rate: Effective interest rate around 5%, expected to decrease in the second half. Working Capital: 50% of revenue, expected to reduce to 45% by year-end. Currency Impact: Significant impact with a 12% delta in normalized earnings between reported and CER.

Warning! GuruFocus has detected 6 Warning Signs with APNHY.

Release Date: March 04, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Aspen Pharmacare Holdings Ltd (APNHY) achieved double-digit growth in revenue and EBITDA in its Commercial Pharma segment, indicating strong operational performance. The company successfully derisked its Commercial Pharma business by addressing challenges in China and Russia, leading to a more stable base for growth. Aspen's Manufacturing segment saw normalized EBITDA more than double, despite no growth in turnover, due to strategic shifts like the heparin toll model. The company is making significant progress in the GLP-1 space, with expectations for early market entry and substantial future growth opportunities. Aspen anticipates strong CER growth in EBITDA and operating cash flow conversion rates exceeding 100%, demonstrating robust financial health.

Negative Points

Currency fluctuations had a significant negative impact on reported financial results, with a notable delta between reported and constant exchange rate figures. The company faces elevated working capital levels due to seasonal inventory builds and the integration of the Sandoz China business, impacting cash flow. Aspen's effective tax rate increased significantly, driven by higher contributions from sterile manufacturing in high-tax jurisdictions and new global tax regulations. The business environment in China remains challenging, necessitating a larger-than-anticipated restructuring effort. Interest rates have peaked, impacting finance costs, although a reduction is anticipated in the second half of the fiscal year.

Story Continues

Q & A Highlights

Q: How does the contribution margin from insulin and other GLP-1 products compare to other Manufacturing products? A: Stephen Saad, Group CEO, explained that for insulins, Aspen operates under an all-in contract where Novo provides all components and API materials, and Aspen handles labor and overhead. For GLP-1s, if Aspen sells these products themselves, they will bear the cost of working capital.

Q: What is the status of the tech transfer for vaccine manufacturing products from the Serum Institute? When will these transfers reflect in turnover and EBITDA? A: Stephen Saad indicated that this was covered in the presentation, implying that the timelines and expectations were already discussed.

Q: What is Aspen's view on oral GLP-1 indications, and will they alleviate supply shortages for injectables? A: Stephen Saad noted that while oral GLP-1s have potential, they first need approval, and their manufacturing cost and efficacy are considerations. There will always be a significant space for injectables, as evidenced by leading players maintaining both oral and injectable products.

Q: Will Aspen consider manufacturing insulin devices, especially for public sector patients? A: Stephen Saad stated that while Aspen is not a device manufacturer, they would consider making insulin in pens, but this decision would depend on the IP holders. Currently, their capacity is focused on vials, with pens expected by 2027.

Q: With ZAR1.3 billion allocated to GLP-1 in H1, what are the future cash flow obligations? Also, why is the actual interest expense lower than H1 2024 despite higher debt? A: Stephen Saad mentioned that most of the GLP-1 investment has been made, with about ZAR300 million remaining. Sean Capazorio, Group CFO, attributed the lower interest expense to currency impacts due to a stronger rand.

Q: Where do you see the investment of GLP-1 usage beyond diabetes and weight management? A: Stephen Saad acknowledged potential uses in areas like cardio, sleep apnea, and addictions, but emphasized waiting for more concrete indications. He noted that so far, all findings have been generally positive.

Q: Does the stringent regulator's review of the GLP-1 dossier mean Aspen has secured supply of peptides for capacity? A: Stephen Saad clarified that regulators focus on the quality and profiles of the supply, not the supply chain itself. Aspen has secured supply and is confident in addressing any regulatory feedback.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments